31: Reproductive and Perinatal Principles

Reproductive and perinatal principles in toxicology are derived from basic science and are applied to clinical practice. This chapter reviews several principles of reproductive medicine that have implications for toxicology, including the physiology of pregnancy and placental xenobiotic transfer, the effects of xenobiotics on the developing fetus and the neonate, and the management of overdose in pregnant women.

One of the most dramatic effects of exposure to a xenobiotic during pregnancy is the birth of a child with congenital malformations. Teratology, the study of birth defects, has principally been concerned with the study of physical malformations. A broader view of teratology includes “developmental” teratogens—xenobiotics that induce structural malformations, metabolic or physiologic dysfunction, or psychological or behavioral alterations or deficits in the offspring, either at or after birth.²⁷⁴ Only 4% to 6% of birth defects are attributable to known pharmaceuticals or occupational and environmental exposures.^44,274

Reproductive effects of xenobiotics may occur before conception. Female germ cells are formed in utero; adverse effects from xenobiotic exposure can theoretically occur from the time of a woman’s own intrauterine development to the end of her reproductive years. An example of a xenobiotic that had both teratogenic and reproductive effects is diethylstilbestrol (DES), which caused vaginal or cervical adenocarcinoma (or both) in some women who had been exposed to DES in utero and also had effects on ­fertility and pregnancy outcome.^26,33

Men generally receive less attention with respect to reproductive risks. Male gametes are formed after puberty; only from that time on are they susceptible to xenobiotic injury. An example of a xenobiotic affecting male reproduction is dibromochloropropane, which reduces spermatogenesis and, consequently, fertility. In general, much less is known about the ­paternal contribution to teratogenesis.³³⁶

Occupational exposures to xenobiotics are potentially important but are often poorly defined. In 2004, it was estimated that there were 41 million women of reproductive age in the workforce.³¹³ Although approximately 90,000 chemicals are used commercially in the United States, only a few thousand of them have been specifically evaluated for reproductive ­toxicity. Many xenobiotics have teratogenic effects when tested in animal ­models, but relatively few well-defined human teratogens have been identified (Table 31–1).²⁸⁶ Thus, most tested xenobiotics do not appear to present a human teratogenic risk, but most xenobiotics have not been tested. Some of the presumed safe xenobiotics may have other reproductive, nonteratogenic toxicities. Several excellent reviews and online resources are available.^{45,104,238,249,274,286}

Another type of xenobiotic exposure for a pregnant woman is intentional overdose. Although a xenobiotic taken in overdose may have direct toxicity to the fetus, fetal toxicity frequently results from maternal pulmonary or hemodynamic compromise, further emphasizing the critical nature of the maternal–fetal dyad.

Xenobiotic exposures before and during pregnancy can have effects throughout gestation and may extend into and beyond the newborn period. In addition, the effects of xenobiotic administration in the perinatal period and the special case of delivering xenobiotics to an infant via breast milk deserve particular consideration.

Many physical and physiologic changes that occur during pregnancy affect both the absorption and distribution of xenobiotics in the pregnant woman and consequently affect the amount of xenobiotics delivered to the fetus.³⁰⁹

Delayed gastric emptying, decreased gastrointestinal (GI) motility, and increased transit time through the GI tract occur during pregnancy. These changes result in delayed but more complete GI absorption of xenobiotics and, consequently, lower peak plasma concentrations. Because blood flow to the skin and mucous membranes is increased, absorption from dermal exposure may be increased. Similarly, absorption of inhaled xenobiotics may be increased because of increased tidal volume and decreased residual lung volume.

An increased free xenobiotic concentration in the pregnant woman can be caused by several factors, including decreased plasma albumin, increased binding competition, and decreased hepatic biotransformation, during the later stages of pregnancy. Fat stores increase throughout pregnancy and are maximal at about 30 weeks; near term, free fatty acids are released, and along with them the lipophilic xenobiotics that may have accumulated in the lipid compartment are released. The increased concentration of circulating free fatty acids can compete with circulating free xenobiotic for binding sites on albumin.

Other factors may lead to decreased free xenobiotic concentrations. Early in pregnancy, increased fat stores, as well as the increased plasma and extracellular fluid volume, lead to a greater volume of distribution. Increased renal blood flow and glomerular filtration may result in increased renal elimination.

Cardiac output increases throughout pregnancy, with the placenta receiving a gradually increasing proportion of total blood volume. Xenobiotic delivery to the placenta may therefore increase over the course of pregnancy.

These processes interact dynamically, and it is difficult to predict their net effect. The concentrations of many xenobiotics, such as lithium, ­gentamicin, and carbamazepine, decrease during pregnancy even if the dose administered is unchanged.¹⁰⁸

Although not specifically related to the physiologic changes occurring during pregnancy, the fetus may be exposed to xenobiotics that accumulated in adipose tissue before pregnancy. For example, malformations typically ascribed to retinoid use occurred in a baby born to a woman whose pregnancy began one year after she discontinued use of the xenobiotic etretinate (retinoic acid).¹⁷¹

Exposure to xenobiotics during pregnancy is common. At some time during pregnancy, as many as 90% of pregnant women take prescription or nonprescription medications other than vitamins and mineral supplements. The most commonly used are analgesics, antipyretics, antimicrobials, and antiemetics.^{17,36,78,217,265} In addition, use of caffeine, tobacco, and alcohol is common. Some pregnant women use xenobiotics to treat a preexisting chronic disease such as epilepsy or a newly diagnosed disease such as deep vein thrombosis. Many women use various prescription and nonprescription xenobiotics before recognizing that they are pregnant.

Pharmaceutical manufacturers are required by law to label their products with respect to use in pregnancy according to standards promulgated by the US Food and Drug Administration (FDA) (Table 31–2).³¹⁴ Similar classification systems have been developed in Sweden and Australia.^8,255,272 The original intent of the US regulations was to inform practitioners about the nature of the available evidence regarding risk in pregnancy. However, the general impression among prescribing health care practitioners is that the categories refer to teratogenic risk, a hierarchy of harmful effects according to the letter categories and an equivalence of risk within each letter category.^85,279,280 For example, in the US system, a category C medication is generally considered more dangerous than a category B medication in pregnancy even though category C is the default category for medications about which there is little or no specific information available and for which the risk is unknown. Approximately 90% of medications are classified as category C.¹⁸⁶

There is significant discordance between the use-in-pregnancy labeling and the teratogenic risk as determined by clinical teratologists,¹⁸⁶ and the FDA system has been criticized for being too conservative.¹⁰³ Manufacturers may label certain medications as category X even when there is only limited information associating the medication with any adverse fetal or neonatal effects. For example, oral contraceptives generally carry a category X classification even though they are not considered teratogenic; category X is assigned because there is no indication for use of oral contraceptives in pregnancy.¹⁶⁹ Certain medications with a category D classification may cause problems only at certain times during pregnancy. Approximately 6% of pregnant women are prescribed medications that carry a category D or X classification, and 1% are prescribed medications that are definitively considered teratogenic.¹⁸ Even medications that are classified as category D or X may only have a very low risk of teratogenicity or other adverse effect, and exposure to these xenobiotics, even during the first trimester, may not be a sufficient indication to terminate a pregnancy.⁹¹

The difficulty regarding appropriate drug labeling reflects many complex questions regarding the use of medications during pregnancy. How should animal data in general be evaluated? How should animal data be extrapolated to humans? How should the teratogenic risk be defined and quantified for any particular xenobiotic? How should the risk of not treating a particular disease be compared with the risk of using a particular medication to treat that disease? Finally, how should the answers to these questions be communicated to practitioners and the public?²⁸⁰

In an attempt to address many of these problems, the FDA has proposed changes to the labeling of medications for use in pregnancy and ­lactation.^134,169,316 These changes include (1) a concise description and estimate of risk of structural teratogenesis, fetal or infant mortality, and impaired growth or physiologic function; (2) details of animal and human data, in particular information from registries, cohort studies, and case-control studies; and (3) clinical considerations such as risk of the disease (treated or untreated) versus risk of the medication, need for dose adjustment in pregnancy, adverse drug reactions specific to pregnancy, monitoring of drug use and effect, effects on labor and delivery, and neonatal complications. Similar labeling rules are proposed for medication effects in the setting of lactation.

Specific current information on individual xenobiotics can be obtained from local and regional teratogen information services⁷ and published books,^{45,104,274,285} some of which also have online versions.^219,249,307 Motherisk is a Canadian program that uses accumulated evidence and experience to advise women about their actual risk of using a particular medication or being exposed to a particular xenobiotic in a current or planned pregnancy.^218,219

Although most women are concerned about the teratogenic effects of medications, in utero exposure to therapeutic medications can have other pharmacologic effects on newborn infants, such as hyperbilirubinemia or withdrawal syndromes.^45,81

Estimates of substance use in pregnancy vary tremendously, depending on the geographic location, practice environment, patient population, and screening method.^56,174 In the National Survey on Drug Use and Health, approximately 16% of pregnant women smoked cigarettes, 11% drank ethanol, 5% used marijuana, 0.25% used cocaine, and 0.1% used heroin.²⁶⁹ Women tend to decrease their exposure to xenobiotics after they know they are pregnant.^37,141,145

With respect to the transfer of xenobiotics from mother to fetus, the placenta functions in a manner similar to other lipoprotein membranes. Most xenobiotics enter the fetal circulation by passive diffusion down a concentration gradient across the placental membranes. The characteristics of a substance that favor this passive diffusion are low molecular weight (MW), lipid solubility, neutral polarity, and low protein binding.²⁴² Polar molecules and ions may be transported through interstitial pores.³¹⁰

Xenobiotics with an MW greater than 1000 Da do not diffuse passively across the placenta, and this characteristic is used to therapeutic advantage. For example, warfarin (MW, 1000 Da) easily crosses the placenta and causes specific fetal malformations.³²² However, heparin (MW, 20,000 Da), which is too large to cross the placenta, is not teratogenic and, consequently, is the preferred anticoagulant during pregnancy. Most therapeutic medications have MWs between 250 and 400 Da and easily cross the placenta. For example, thiopental is highly lipid soluble and crosses the placenta rapidly. Fetal plasma concentrations reach maternal concentrations within a few minutes. Neuromuscular blockers such as vecuronium are more polar and cross the placenta slowly.⁸⁸

Although ionization is a limiting factor for diffusion, some highly charged molecules can still diffuse across the placenta. Valproic acid (pK_a of 4.7) is nearly completely ionized at physiologic pH, yet there is rapid equilibration across the placental membrane. The small amount of xenobiotic that exists in the nonionized form rapidly crosses the placenta, and as the equilibrium is reestablished, a new, small amount of nonionized xenobiotic becomes available for diffusion.²²³

Fetal blood pH changes during gestation. Embryonic intracellular pH is high relative to the intracellular pH of the pregnant woman. ­During this developmental stage, weak acids diffuse across the placenta to the embryo and remain there because of “ion trapping.” Many teratogens, such as valproic acid, trimethadione, phenytoin, thalidomide, warfarin, and isotretinoin, are weak acids. Although ion trapping does not explain the mechanism of teratogenesis, it may explain how xenobiotics accumulate in an embryo. Late in gestation, the fetal blood is 0.10 to 0.15 pH units more acidic than the maternal blood; this pH differential may permit weakly basic xenobiotics to concentrate in the fetus during this period.²⁴²

The relative concentrations of protein binding sites in the pregnant woman and fetus also have an impact on the extent of xenobiotic transfer to the fetus.²⁴² As maternal free fatty acid concentrations increase near term, these fatty acids can displace xenobiotics such as valproic acid or diazepam from maternal protein binding sites and make more free xenobiotic available for transfer to the fetus. Fetal albumin concentrations increase during gestation and exceed maternal albumin concentrations by term. Because the fetus does not have high concentrations of free fatty acids to compete for protein binding sites, these sites are available for binding the xenobiotics. At birth, when neonatal free fatty acid concentrations increase two- to threefold, they displace stored xenobiotic from the binding protein. In the cases of valproic acid and diazepam, the elevated concentrations of free xenobiotic have adverse effects on the newborn infant.^{111,143,223,248}

The placenta may also affect xenobiotic presentation to the fetus by ion trapping and xenobiotic metabolism. The placenta blocks the transfer of some positively charged ions such as cadmium and mercury¹²² and may even accumulate them. This barrier does not necessarily protect the fetus, however, because these metal ions interfere with normal placental function and may lead to placental necrosis and subsequent fetal death.²¹⁶

The placenta contains xenobiotic-metabolizing enzymes capable of performing both phase I and phase II reactions (Chaps. 13 and 23). However, the concentration of biotransforming enzymes in the placenta is significantly lower than that in the liver, and it is unlikely that the level of enzymatic activity is protective for the fetus. Moreover, the fetus may be exposed to reactive intermediates that form during these processes. On the other hand, glutathione may also be present in the placenta and detoxify some of these reactive intermediates.¹⁵⁰

Placental transfer of xenobiotics can have a positive effect when it delivers desired therapies to the fetus. For example, if a fetus is found to have a supraventricular tachycardia or atrial flutter, digoxin can be given to the mother to treat the tachydysrhythmia in the fetus.^162,263

A basic premise of teratogenicity is that the particular toxic effects of a xenobiotic are determined by the stage of development of the embryo or fetus.^41,281 Although the fertilized ovum is generally thought to be resistant to toxic insult before implantation,⁴¹ xenobiotics in the fallopian or uterine secretions may prevent implantation of the embryo. Xenobiotic exposure leading to cell loss or chromosomal abnormalities may also lead to loss of the embryo, possibly even before pregnancy has been detected. If the preimplantation embryo survives a xenobiotic exposure, the functional cells usually proceed to normal development.²⁸¹ Teratogens that act in such a manner elicit an “all-or-none response”; that is, the exposed embryo will either die or go on to normal development.

The dose–response curve of environmental xenobiotics can have deterministic (threshold) or stochastic (no threshold) effects.⁴² Mutagenic and carcinogenic events are stochastic phenomena. Teratogenesis is a deterministic phenomenon with a threshold dose below which no effects occur. As the dose of the teratogen increases above the threshold, the magnitude of the effect increases. The effects might be the number of offspring that die or develop malformations or the extent or severity of malformations. Radiation is one agent that has both deterministic effects (eg, microcephaly and growth retardation) and stochastic effects (induction of leukemia). Strictly speaking, teratogenic effects are those that occur at doses that do not cause maternal toxicity because maternal toxicity itself might be responsible for an observed adverse or teratogenic effect on the developing organism.⁴¹

Organogenesis occurs during the embryonic stage of development between days 18 and 60 of gestation. Most gross malformations are determined before day 36, although genitourinary and craniofacial anomalies occur later.⁴¹ The period of susceptibility to teratogenic effects varies for each organ system (Fig. 31–1). For instance, whereas the palate has a very short period of sensitivity, lasting approximately 3 weeks, the complete development of the central nervous system (CNS), including neurogenesis and differentiation, arborization, synaptogenesis and synaptic organization, and myelinization and gliogenesis, remains susceptible throughout the fetal period and into the neonatal period and infancy.

Theoretically, knowing the exact time of teratogen exposure during gestation would allow prediction of a teratogenic effect; this is true in ­animal models, where the dose and time of exposure can be strictly controlled. It is also true for thalidomide in which different limb anomalies are specifically related to exposures on particular days of gestation.²⁸¹ In many clinical situations, for xenobiotics administered either for a short course or chronically, relating teratogenicity to a particular xenobiotic exposure is difficult because the exact time of conception and the exact time of exposure are unknown. This is particularly true when the primary exposure precedes the identification of pregnancy but there is secondary or ongoing exposure during pregnancy as xenobiotic is redistributed from tissue storage sites.¹⁷¹

During the fetal period, formed organs continue their cellular differentiation and grow to functional maturity. Exposure to xenobiotics such as cigarettes and their toxic constituents during this period generally lead to growth retardation. Teratogenic malformations or death may still occur as a result of disruption or destruction of growing organs, as has resulted from exposure to angiotensin-converting enzyme inhibitors during the second and third trimesters.³⁰

Another concern during the fetal period is the initiation of carcinogenesis. Significant cellular replication and proliferation lead to a dramatic growth in size of the organism. At the same time, when the fetus is exposed to xenobiotics, development of biotransformation systems may expose the organism to reactive metabolites that might initiate tumor formation. Some tumors, such as neuroblastoma, appear so early in postnatal life that their prenatal origin is suggested. In pregnant rats given ethylnitrosourea during the embryonic period, lethal or teratogenic effects occur.²⁵⁰ If ethylnitrosourea is administered during the fetal period, there is an increased incidence of tumors in the offspring. Clear cell vaginal and cervical adenocarcinomas occur in the female offspring of women exposed to DES during pregnancy.³³

Cytotoxicity is one mechanism of teratogenesis and is the characteristic result of exposure to alkylating or chemotherapeutic agents. Aminopterin, for example, inhibits dihydrofolate reductase activity and leads to suppression of mitosis and cell death. If exposure to a cytotoxic xenobiotic occurs very early in development, the conceptus may die, but sublethal exposure during organogenesis may result in maldevelopment of particular structures. There is evidence that after cell death, the remaining cells in an affected region may try to repair the damage caused by the missing cellular elements. This “restorative growth” may lead to uncoordinated growth and exacerbate the original malformation.

In the case of the cytotoxics, the mechanism of action is understood, although it is not always clear why particular xenobiotics affect particular structures. With other xenobiotics, the structural effects have a clearer relationship to the site of action. For instance, when corticosteroids are administered in large doses to some experimental animals during the period of organogenesis, malformations of the palate occur. Glucocorticoid receptors are found in high concentrations in the palate of the developing mouse embryo.²⁴³ Corticosteroid exposure can also cause cleft palate in humans at a low frequency.^236,285

Caloric deficiency is not considered teratogenic during the period of organogenesis; however, specific nutritional or vitamin deficiencies can be. In particular, there is an increased incidence of neural tube defects (anencephaly and spina bifida) associated with dietary folate deficiency, although the specific mechanism of teratogenesis is unknown. To ensure that all women of childbearing age have adequate folate stores by the time they become pregnant and during their pregnancy and to reduce the number of severe birth defects, it is important for women to have folate supplementation either as vitamin or dietary supplements even before they become pregnant. Because fortification of grain products is considered critical to help accomplish this goal, the FDA requires US manufacturers to add folic acid to enriched breads, cereals, flours, corn meals, pastas, rice, and other grain products.²³⁰

Ethanol affects fetuses both directly and indirectly. The craniofacial malformations that occur in fetal alcohol syndrome (FAS) probably result from the effects of ethanol during the period of organogenesis. Growth retardation may result from direct effects of ethanol on fetal growth or from indirect effects resulting from ethanol-induced maternal nutritional deficiencies.

For most women, pregnancy and the postpartum period are a period of emotional happiness. However, women have a lifetime prevalence of depression that is two to three times higher than men, and for some women, psychiatric illness during pregnancy, particularly depression and anxiety, represents a significant complication. A new first episode or recurrence of major depression occurs in approximately 3% to 5% of pregnant women and 1% to 6% of postpartum women; an additional 5% to 6% of women in each period will have minor symptoms of depression.¹⁰⁷ Overall, these rates of depression are about the same in pregnant and nonpregnant women; however, during the postpartum period, the onset of new episodes of depression may be three times higher than for nonpregnant women. Pregnant teenagers may also be at higher risk of depression in pregnancy.¹⁸⁴

Postpartum “baby blues” are common; typically involve relatively mild symptoms including mood swings, irritability, anxiety and crying spells; and generally resolve by 2 weeks postpartum.¹⁹¹ Postpartum blues do not include suicidal ideation. True depression is manifested by feelings of hopelessness or helplessness and may include suicidal ideation.¹⁹¹ Postpartum psychosis, typically associated with bipolar disorder, is uncommon, but it represents a true psychiatric emergency because there is a high risk of ­suicide, infanticide, or both.¹⁹¹

Risk factors for perinatal depression include an unplanned pregnancy, ambivalence about the pregnancy, poor social support, marital difficulties, adverse life events, and chronic stressors such as financial problems.^65,173,319 Of substantial importance is a personal or family history of depression, particularly previous perinatal depression. Discontinuation of antidepressant represents a significant risk for relapse of disease, although relapse is possible even while a woman is receiving an antidepressant. Additional risk factors for depression include miscarriage, stillbirth, and preterm delivery.²⁷⁶

Depression in pregnancy has adverse effects on both the mother and the fetus.³⁵ For the pregnant woman, adverse effects include noncompliance with prenatal care; self-medication with tobacco, alcohol, and drugs; poor sleep; poor appetite; and poor weight gain. In addition, there may be an increased risk of spontaneous abortion, preeclampsia, preterm delivery, and growth retardation. For many of these outcomes, it is difficult to differentiate the contributions from multiple confounding and interacting factors, including psychopathology, socioeconomic status, acute and chronic stressors, smoking, and the use of alcohol and other drugs of abuse. Infants born to women being treated with antidepressant medications are also at risk for neonatal withdrawal symptoms.¹⁵⁸

One of the most extreme outcomes of depression is suicide. Suicidal ideation occurs in about 5% of pregnant women in community samples and up to 20% in women with underlying psychiatric illness.^184,226 Even so, suicide and suicide attempts during pregnancy are uncommon. Each year a small number of women die during pregnancy or the postpartum period; 1% to 5% of these pregnancy-related deaths may be the result of suicide.^54,76,231 Between 2% and 12% of women who attempt or commit suicide may be pregnant.^157,240,332 Overall, completed suicide occurs less frequently during pregnancy.^19,184,205 Psychiatric illness, including previous suicide attempts, predisposes to suicide attempts in pregnancy. Acute stressors leading to impulsive acts account for most of the uncompleted suicide attempts; these reasons include loss of a lover, economic crisis, prior loss of children, and unwanted pregnancy, and desire for an abortion.^72,180,332 Fewer than half of the suicide attempts are specifically related to a pregnancy-related problem.

Women who complete suicide typically have more severe psychiatric illness. In particular, these women are likely to use more violent means of suicide such as hanging or self-inflicted gunshot wounds, although poisonings are a significant contributor to these deaths.²³¹ In addition, substance and alcohol use is a significant contributing factor in many cases; additionally, some pregnancy-related deaths may be secondary to complications of substance use, such as overdose.²³¹ Initiation of child-protection proceedings, particularly in the setting of maternal substance use, may be an additional risk factor for postpartum suicide.²³¹

Ingestion of xenobiotics is the most common method of attempted suicide during pregnancy and the postpartum period.^65,240,245 There are about 9000 xenobiotic exposures in pregnant women reported to the AAPCC annually, which account for less than 1% of the approximately 1 million reported adolescent and adult exposures. The patterns of xenobiotic exposure are similar to those of adult exposures in general with analgesics being the most common exposure. However, according to AAPCC data, there are relatively more exposures to cleaning substances, pesticides, fumes, and vitamins, but there are relatively fewer exposures to sedative–­hypnotics, antidepressants, and cardiovascular agents; the absolute differences are small (Chap. 136). Some of these xenobiotic exposures may be attempts to terminate pregnancy (Chap. 21).²⁴⁰ As with most poisonings overall, the severity of poisoning in pregnant women is typically minor.^226,231

In one US national sample, 1659 pregnant women had poisoning-related hospitalizations, representing 0.04% of all hospitalized pregnant women and approximately 10% of injury-related admissions of pregnant women. A total of 244 of these women (15%) delivered their babies during these hospitalizations related to poisoning.¹⁶⁶

In national samples from both the United States and England, approximately 2% to 3% of deaths in pregnancy and the immediate postpartum period follow suicidal poisoning.^54,231 The AAPCC reports approximately one to two deaths per year in pregnant women, which represents approximately one to two per 1000 AAPCC-reported adult deaths overall, two to four per 1000 deaths in adult women, and approximately one death per 10000 xenobiotic exposures in pregnancy (Chap. 136). In a combined Hungarian series of pregnant women who had suicidal poisonings, 19 of 1044 (1.8%) died.⁷³

Any woman who attempts suicide during pregnancy or the post­partum period should have a psychiatric evaluation after she is medically stabilized. In particular, a growing number of specialized units or teams focus on pregnant and postpartum women and attempt to keep women and infants together in the postpartum period.^191,231

Managing any acute overdose during pregnancy provokes discussion of several questions. Is the general management different? Do altered metabolism and pharmacokinetics increase or decrease the woman’s risk of morbidity or mortality from a xenobiotic overdose? Is the fetus at risk of poisoning from a maternal overdose? Is there a teratogenic risk to the fetus from an acute overdose or poisoning? Is the use of an antidote contraindicated, or should use be modified? When should a potentially viable fetus be emergently delivered to prevent toxicity? When should termination of a pregnancy be recommended?

As described earlier, physiologic changes during pregnancy affect pharmacokinetics; xenobiotics taken in overdose also have unpredictable toxicokinetics. In any significant overdose during pregnancy, pregnancy-related alterations in pharmacokinetics are unlikely to protect the woman from significant morbidity or mortality.

Although a single high-dose exposure to a xenobiotic during the period of organogenesis might seem analogous to an experimental model to induce teratogenesis, most xenobiotics ingested as a single, acute overdose do not induce physical deformities.⁷⁴ Anticonvulsants are teratogenic and may be ingested in toxic doses, but their teratogenicity is probably related more to chronic exposure. Acute acetaminophen (APAP) toxicity in the first trimester may lead to an increased risk of spontaneous abortion,²⁵³ suggesting a teratogenic effect similar to the all-or-none response described earlier. In general, however, it is extremely difficult to ascribe teratogenicity to a particular xenobiotic exposure based on a single case report. There is, for example, a report of multiple severe congenital malformations in the stillborn fetus of a woman who overdosed on isoniazid during the 12th week of pregnancy.¹⁷⁸ However, because the background incidence of congenital malformations is 3% to 6%, it is almost impossible to determine for a single individual whether a particular exposure is the etiology of observed malformations.⁷⁵ The Budapest Registry of Self-Poisoned Patients uses this construct to screen for possible teratogenic effects of xenobiotics in overdose.^73,74 Considering the successful outcome of most pregnancies that progress to term after an acute overdose, it is very unlikely that the small risk of teratogenesis would lead to a recommendation for termination of pregnancy after an acute overdose of most xenobiotics.

In general, any condition that leads to a severe metabolic derangement in a pregnant woman is likely to have an adverse impact on her developing fetus. Therefore, the management of overdose in a pregnant woman usually follows the principles outlined in Chap. 4, with close attention paid to the airway, oxygenation, and hemodynamic stability. The use of naloxone or dextrose has not been specifically assessed in pregnancy but should be guided by the same considerations raised in managing the nonpregnant patient with alterations in respiratory or neurologic function. Opioid-induced respiratory failure in a pregnant patient will lead to fetal hypoxia and adverse effects; opioid withdrawal in a pregnant woman, whether induced by abstinence or the use of naloxone, may adversely affect the fetus or the pregnancy. Consideration of the benefits and risks of the use of naloxone for an opioid-poisoned woman in respiratory distress or coma suggests that reduced morbidity, for both the mother and fetus, may be achieved by the use of carefully titrated doses of naloxone to minimize the likelihood of maternal withdrawal (Chap. 38 and Antidotes in Depth: A4).

Gastrointestinal decontamination is frequently a part of the early management of acute poisoning in nonpregnant patients. Gastric lavage is not specifically contraindicated for pregnant patients, and the usual concerns about protecting the airway apply.

There is no specific contraindication to the use of activated charcoal in a pregnant woman. There may be a specific role for whole-bowel irrigation (WBI) in the management of several xenobiotic exposures, particularly in the treatment of iron overdose in pregnancy.³¹⁷ The use of oral polyethylene glycol is safe in pregnant women.²²⁴

Almost all antidotes are designated as FDA pregnancy-risk category C; that is, there is little specific information to guide their use. Ethanol is labeled as category D (positive evidence of risk), although this is presumably related to chronic use throughout pregnancy. Fomepizole, which has replaced ethanol as the preferred antidote for toxic alcohol poisoning, is labeled as category C. Pyridoxine and thiamine are category A xenobiotics; N-acetylcysteine (NAC), magnesium, glucagon, and naloxone are category B xenobiotics.

Thus far, there are no reports of adverse effects on a fetus from antidotal treatment of a poisoned pregnant woman. Conversely, in at least one case, withholding deferoxamine therapy may have contributed to the death of both a woman and her fetus.^201,302

APAP is the most common analgesic and antipyretic agents used during pregnancy and is also one of the most common xenobiotic overdoses during pregnancy. There are two published series of acute APAP overdose during all trimesters of pregnancy in addition to multiple casereports.^{24,50,105,119,133,165,177,190,211,239,253,257,258,264,267,270,299,320} Overall, most pregnant women recover from an APAP ingestion without adverse effects to themselves or their babies.

Of 28 women with first trimester exposures who continued their pregnancies, five women with toxic serum APAP concentrations and 14 with nontoxic concentrations delivered full-term newborns; in one case, both the mother and fetus died; and eight women had spontaneous abortions. Five of these eight had toxic serum concentrations and received NAC (one within 8 hours and four between 12 and 17 hours after ingestion).

Of 31 women with second trimester exposures who continued their pregnancies, seven women with toxic serum APAP concentrations and 20 with nontoxic concentrations delivered full-term babies; one woman with a nontoxic serum concentration and one woman who developed hepatotoxicity delivered premature infants; and two women with nontoxic serum APAP concentrations had spontaneous abortions probably unrelated to the overdose.

Of 54 women with third trimester exposures, 15 women with toxic serum APAP concentrations and 26 with nontoxic concentrations delivered full-term babies; eight woman with a toxic serum concentration, four of whom developed hepatotoxicity, and two women with nontoxic concentrations delivered premature infants; two women with severe hepatotoxicity delivered stillborn infants who also showed signs of hepatotoxicity; and one woman with severe hepatotoxicity delivered an infant who died at 34 hours of life.

There are also several case reports of adverse pregnancy outcome in the setting of chronic use of APAP or acute overdose associated with chronic substance use.^{55,133,167,192,253,311} It is difficult to interpret these reports with respect to specific APAP effect because of the confounders of chronic disease, chronic use, or use of additional medications or substances.

Although APAP at recommended doses is considered safe inpregnancy,¹⁸¹ in overdose, it puts the developing fetus at risk. As the cases demonstrate, APAP crosses the placenta to reach the fetus. There may be an increased risk of spontaneous abortion after overdose during the first trimester, particularly in the setting of toxic serum APAP concentrations and delayed NAC therapy.²⁵³ There is also a question about whether overdose during the first trimester can lead to late sequelae, for instance, premature labor.

Some experimental work might explain early pregnancy loss after overdose. APAP prevented the development of preimplantation (two-cell stage) mouse embryos in culture, an effect that was not associated with alterations in glutathione concentrations,¹⁷⁵ and led to abnormal neuropore development in cultured rat embryos.²⁹⁸ These data suggest that APAP may be directly toxic to the immature organism. However, other work reported that similar embryotoxic effects were associated with reductions in glutathione concentrations³²⁷ and that N-acetyl-p-benzoquinoneimine (NAPQI) produced nonspecific toxicity when added to the rat embryo culture medium.²⁹⁸

The fetal liver has some ability to metabolize APAP to a reactive inter­mediate in vitro. Cytochrome P450 (CYP) activity was detected in intact hepatocytes, as well as in microsomal fractions isolated from the livers of fetuses aborted between 18 and 23 weeks of gestation. This fetal hepatic CYP activity increased between 18 and 23 weeks (the only period studied) but was maximally only 10% of the activity of hepatocytes isolated from adults after brain death.²⁶¹ In two clinical cases, cysteine and mercapturate conjugates were identified in newborns exposed to APAP in utero, suggesting that the fetus and neonate can metabolize APAP through the CYP system.^177,257 These data suggest that the fetus in utero and the neonate can generate a toxic metabolite. The clinical cases suggest that the fetal liver is susceptible to injury, although whether this fetal hepatoxicity is related to fetal APAP toxicity, maternal toxicity, or postmortem changes is unclear.

This CYP activity has not been further characterized. However, CYP2E1, one of the cytochromes responsible for APAP metabolism, is present in human fetal tissues as early as 16 weeks of gestation.²¹⁴ CYP3A4 and CYP1A2 are also involved in APAP metabolism but are not present in fetal liver. CYP3A7 is a functional fetal form of the CYP3 family, but its metabolic activity with respect to APAP has not been studied.¹²⁰

The most relevant clinical questions relate to management of overdose during the third trimester. Can APAP overdose lead to premature labor even if a pregnant woman does not have a toxic serum concentration or develop hepatotoxicity? Should a woman be emergently delivered following overdose? Does NAC treatment of the mother help the fetus? What is the appropriate treatment of a neonate exposed to APAP in utero?

The clinical cases may help address the last two questions (Table 31–3).Seven women whose pregnancies were all at less than 36 weeks of gestation, developed hepatotoxicity. Two infants died in utero, and one infant died on the second day of life with evidence of hepatotoxicity. The other four infants experienced problems associated with prematurity but did not develop obvious hepatotoxicity. One of these four had an exchange transfusion and an unexplained death at 3 months of age. Five women whose pregnancies were all at 36 or more weeks of gestation did not develop hepatotoxicity. One infant had an exchange transfusion and did not develop hepatotoxicity but died of sudden infant death syndrome (SIDS) at 5 months of age. One infant received intravenous (IV) NAC and had a transient elevation of aspartate aminotransferase (AST) and prothrombin time. Two infants were not treated, and both did well, although one had a transient elevation of AST. One infant was born 6 weeks after the overdose and was normal.

Severe maternal hepatoxicity that is associated with any sign of fetal distress is an indication for urgent delivery. Although a fetus with prolonged exposure to APAP in utero is at risk of developing severe hepatotoxicity, not all at-risk infants are affected. What role gestational age, maternal disease state, or other maternal factors may play is unknown. Although there are insufficient case data to suggest that APAP overdose per se is an indication for urgent delivery, there may be an indication for urgent delivery when the maternal serum APAP concentration is in the toxic range but hepatotoxicity has not yet developed.³⁰⁶ The clinical cases suggest that significant APAP overdose with or ­without hepatotoxicity may precipitate premature labor and that even women with nontoxic serum concentrations may be at an increased risk.

In two cases, exchange transfusion was used to treat the exposed neonate. In both cases, the APAP half-life was prolonged, and in neither case was this affected by the transfusion. Disturbingly, these two infants had unexplained deaths at several months of age. There are currently no data supporting exchange transfusion as therapy for prenatal exposure.

A pregnant woman with acute toxic APAP ingestion should be treated with NAC (Chap. 35 and Antidotes in Depth: A3). This therapy is designed to treat the mother. Maternal hepatoxicity and delayed NAC therapy are associated with fetal toxicity²⁵³; whether NAC therapy can prevent later sequelae such as premature delivery is unclear. Although NAC did not cross the sheep placenta in vivo²⁸² or the perfused human placenta in vitro,¹⁴¹ NAC was found in cord blood after administration to four mothers before delivery.¹³³­ Even if NAC does cross the placenta, whether it prevents fetal hepatotoxicity is unknown because not all exposed fetuses develop hepatotoxicity.

Iron is also commonly ingested during pregnancy; maternal toxicity is generally greater than fetal toxicity. In two reported cases, normal babies were delivered, although the mothers died.^233,251 In another case, the mother had severe iron toxicity with acidosis, shock, kidney failure, and disseminated intravascular coagulation but was not treated with deferoxamine because of concerns about its teratogenic risks. Instead, the mother received an exchange transfusion followed 45 minutes later by a spontaneous abortion of the 16-week fetus.^201,302 Neonatal and cord blood iron concentrations were not elevated. In several cases, pregnant women who had signs and symptoms of iron poisoning and elevated serum iron concentrations were treated with deferoxamine and subsequently delivered normal babies.^{34,155,170,246,275,312}

Although the placenta transports iron to the fetus efficiently,²³ it also blocks the transfer of large quantities of iron. In a sheep model of iron poisoning, only a small amount of iron was transferred across the placenta despite significantly elevated serum iron concentrations.⁷¹

Deferoxamine is an effective antidote for iron poisoning (Chap. 46 and Antidotes in Depth: A7), but it is reported to be an animal teratogen that causes skeletal deformities and abnormalities of ossification (FDA class C pregnancy risk). An animal model observed similar effects but only with doses of deferoxamine that caused maternal toxicity.³⁸ Experimentally, in sheep, deferoxamine was minimally transported across the placenta⁷¹; therefore, the reported fetal effects may be secondary to chelation of essential nutrients (eg, trace metals) on the maternal side of the placenta.³⁰⁶

In clinical case reports of iron overdose for which deferoxamine was used, there have been no adverse effects on the fetus, although most have been either second or third trimester poisonings.^{34,155,170,233,246,275,312} In a case series of 49 patients with iron poisoning during pregnancy, few of the patients exhibited any clinical toxicity other than vomiting and diarrhea; 25 received deferoxamine, most by the oral route.²¹⁰ One woman with a first trimester overdose, eight women with second trimester overdoses, and 12 women with third trimester overdoses were treated with deferoxamine and subsequently delivered full-term infants. One infant whose mother overdosed at 30 weeks of gestation had webbed fingers on one hand. One woman overdosed at 20 weeks had minimal clinical toxicity, received deferoxamine, and delivered a 2.5-kg male infant at 34 weeks of gestation. One woman with a first trimester overdose and two women with second trimester overdoses elected to terminate their pregnancies.

Further support for the safe use of deferoxamine in pregnancy is the experience with its use for pregnant women with thalassemia major. For many years, deferoxamine has been administered as part of the therapy for posttransfusion iron overload without adverse effects.²⁸⁹

Deferoxamine is probably safe for use in pregnant women. Considering the potentially fatal nature of severe iron poisoning, deferoxamine should be administered when signs and symptoms indicate significant poisoning.

Iron overdose may be one of the few specific indications for WBI because iron is not adsorbed to activated charcoal (Antidotes in Depth: A1 and A2). A case report demonstrated elimination of pill fragments after treatment of a pregnant woman with WBI.³¹⁷

Carbon monoxide is the leading cause of poisoning fatalities in the United States. In contrast to iron and most other xenobiotics, when pregnant women are exposed to carbon monoxide, the fetus may be at greater risk of toxicity than the expectant woman. There are reports of both the mother and fetus dying; the mother surviving but the fetus dying; and both the mother and fetus surviving but with an adverse neonatal outcome, primarily brain damage resembling that seen after severe cerebral ischemia.^{51,69,163,187,202,228,317,335} Similar clinical effects have also been observed in animal models.^87,112,188

The case literature suggests an increased risk of poor fetal outcome with clinically severe maternal poisoning or significantly elevated carboxyhemoglobin concentrations.^163,228 Women with minimal symptoms or low concentrations of carboxyhemoglobin have a low risk of fetal toxicity, but a lower limit of exposure without effect has not been specifically defined.¹⁶³

In animal models, under experimental conditions, the fetus has a carboxyhemoglobin concentration 10% to 15% higher than the mother.^128,188 After exposure to carbon monoxide, the fetus achieves peak carboxyhemoglobin concentrations 58% higher than those achieved by the mother at steady state, and the time to peak concentration is also delayed compared with that of the mother. Similarly, the elimination of carbon monoxide occurs more slowly in the fetus than in the mother.^128,187,188 One case report describes such a phenomenon: after 1 hour of supplemental oxygen, the maternal carboxyhemoglobin concentration was 7% and the fetal carboxyhemoglobin concentration was 61% at the time of death in utero.⁹³

Carbon monoxide leads to fetal hypoxia by several mechanisms: (1) maternal carboxyhemoglobin leads to a decrease in the oxygen content of maternal blood, and therefore less oxygen is delivered across the placenta to the fetus, which normally has an arterial PO₂ of only 20 to 30 mm Hg; (2) fetal carboxyhemoglobin causes a decrease in fetal PO₂; (3) carbon monoxide shifts the oxyhemoglobin dissociation curve to the left and decreases the release of oxygen to the fetal tissues (an exacerbation of the physiologic left shift found with normal fetal hemoglobin); and (4) carbon monoxide may inhibit cytochrome oxidase or other mitochondrial functions (Chap. 125).

The treatment for severe carbon monoxide poisoning is hyperbaric oxygen therapy (HBO) (Chap. 125 and Antidotes in Depth: A38). There are questions about the use of HBO in pregnant women because animal models suggest HBO adversely affects the embryo or fetus.^{99,215,273,305} The applicability of these animal models to humans is difficult to assess; many of the animal models used hyperbaric conditions of greater pressures and duration than those clinically used for humans.

Hyperbaric oxygen therapy has been used therapeutically for carbon monoxide poisoning in pregnancy with good results reported, although there are limited data on the long-term follow-up of the children.^{47,98,106,116,129,163,318} One large series reported 44 women who were exposed to carbon monoxide during pregnancy and were treated with HBO, regardless of clinical ­severity or gestational age: 33 had term births, one had a premature delivery 22 weeks after HBO during an episode of maternal fever, two had spontaneous miscarriages (one 12 hours after severe poisoning and one 15 days after mild poisoning), one delivered a child with Down syndrome, one had an elective abortion, and six were lost to follow-up.⁹³ Details regarding trimester of exposure, maternal carboxyhemoglobin concentration, and severity of symptoms are not available, making it difficult to interpret the reported adverse outcomes. Although HBO appears safe for pregnant women and seems to present little risk to the fetus, it is not clear whether HBO prevents carbon monoxide–related fetal toxicity.

Hyperbaric oxygen therapy should be considered for any pregnant woman exposed to carbon monoxide, especially for a woman with an elevated serum carboxyhemoglobin concentration or any evidence of fetal distress. To allow the fetal carboxyhemoglobin to be eliminated, if HBO therapy is not available, 100% oxygen should be administered to a pregnant woman for five times as long as the time needed for her carboxyhemoglobin concentration to return to the normal range. Thus, if a pregnant woman’s carboxyhemoglobin concentration returns to normal in 30 minutes, she should continue to receive 100% oxygen for a total of 150 minutes.

Illicit and licit substance use during pregnancy and its effects on the woman, on the pregnancy, and on the fetal and postnatal development are complex.

With the increased use of cocaine during the latter half of the 1980s and 1990s, there was great interest in determining the effects of cocaine use during pregnancy. As research in this area progressed, many of the critical methodologic issues related to substance use research were highlighted.^{100,140,179,225,337}

Substance-using women often have multiple risk factors for adverse pregnancy outcomes, such as low socioeconomic status, polysubstance use, ethanol and cigarette use, sexually transmitted infections, AIDS, malnutrition, and lack of prenatal care. Lack of prenatal care is highly correlated with premature birth, and smoking is associated with spontaneous abortion, growth retardation, and SIDS.^152,330 Other factors not specifically related to substance use such as age, race, gravidity, and prior pregnancies also affect pregnancy outcome. Each of these factors represents a significant potential confounding variable when the effects of a particular xenobiotic such as cocaine or marijuana are evaluated during pregnancy and must be controlled for in research design. Many of these factors are also significant confounders in evaluation of postnatal growth and development.

There may be bias in the selection of study subjects. For example, if all the patients are selected from an inner-city hospital obstetrics service, there is potential for overestimating the effects of the xenobiotic being studied. If cohorts are followed over a long time, study subjects are frequently lost to follow-up. Are the ones who continue more motivated, or do they have more problems that need attention?

Categorizing patients into substance-use groups is difficult. Self-reporting of substance use is frequently unreliable or inaccurate, and making determinations about the nature, frequency, quantity (dose), or timing (with respect to gestation) of xenobiotic exposure is difficult. Because substance users frequently use multiple xenobiotics, it may be difficult to categorize subjects into particular xenobiotic-use groups, and patients using different xenobiotics may be grouped together. In fact, there may be no actual xenobiotic-free control groups.

When urine drug screens are used to identify substance users, there is a high probability of false negatives because drug screens reflect only recent use. This factor is particularly important because substance use tends to decrease later in pregnancy, and a negative urine drug screen in the third trimester or at delivery may fail to identify a woman who was using xenobiotics early in pregnancy. Testing for xenobiotics in hair or meconium may improve the accuracy of the analysis with regard to the entire pregnancy.^39,160

Another bias involves selection of infants who are exposed to xenobiotics. Evaluating newborns who are “at risk,” show signs of withdrawal, or have positive urine drug screens will miss some exposed infants. When research concerns the neurobehavioral development of children exposed in utero to substances, it is important that the examiners performing the evaluation be blinded to the infants’ xenobiotic exposure category.

Finally, there may be a bias against publishing research that shows a negative or no significant effect.¹⁶¹

Ethanol

Chronic ethanol use during pregnancy produces a constellation of fetal effects. The most severe effects occur in the FAS, which is characterized by (1) intrauterine or postnatal growth retardation; (2) intellectual disability or behavioral abnormalities; and (3) facial dysmorphogenesis, particularly microcephaly, short palpebral fissures, epicanthal folds, maxillary hypoplasia, cleft palate, a hypoplastic philtrum, and micrognathia.^32,200 A child can be diagnosed with FAS even when a history of regular gestational alcohol use cannot be confirmed.

In an attempt to formalize diagnostic criteria for FAS and other gestational alcohol-related effects, the Institute of Medicine proposed some additional descriptors that are in common use.³⁰⁰Partial FAS is applied to a child with some of the characteristic facial features and with growth retardation, neurodevelopmental abnormalities, or other behavioral problems. Alcohol-related birth defects are congenital anomalies other than the characteristic facial features described earlier, for example, cleft palate, which sometimes occurs with regular gestational alcohol use. Alcohol-related neurodevelopmental disorder describes neurodevelopmental abnormalities or other behavioral problems, which sometimes occur with regular gestational alcohol use. Fetal alcohol spectrum disorders (FASDs) is an umbrella term describing the range of effects that can occur in an individual whose mother drank alcohol during pregnancy.^32,294

Differential expression of the syndrome may reflect the effects of varying quantities of ethanol ingested at critical periods specific for particular effects. The craniofacial anomalies probably represent teratogenic effects during organogenesis, but some CNS abnormalities and growth retardation may result from adverse effects later in gestation.

There is considerable controversy about what amount of alcohol consumption can cause FASD.^221,229 Approximately 10% of women consume some alcohol during pregnancy, 2% are frequent users, and 2% binge. Of women who might become pregnant, about 50% drink some alcohol, 13% drink frequently, and 12% binge.⁵² Some researchers believe that the FASD is a result of alcoholism—chronic regular use or frequent binging—rather than to low concentrations of gestational ethanol exposure, no matter how little or how infrequent.^4,115 A high level of consumption would be in the range of 50 to 100 mL of 100% ethanol (four to six “standard” drinks of hard liquor) regularly throughout pregnancy³⁰⁰ or binge drinking (at least five standard drinks per occasion), with a significantly elevated peak blood ethanol concentration.^3,197 Literature suggests that behavioral abnormalities are associated with the reported consumption of as little as one drink per week.²⁹⁵ In this regard, neither a no-effect amount nor a safe amount of ethanol use in pregnancy has been determined,¹⁴⁹ and therefore the US Surgeon General recommends no alcohol consumption during pregnancy.²³²

The incidence of FAS is 0.5 to 3 per 1000 live births; 4% of women who drink heavily may give birth to children with FAS.^2,207 This means that several hundred children with FAS and several thousand with fetal alcohol effects will be born each year; thus, ethanol use is considered the leading preventable cause of intellectual disability in this country.³⁰⁰ Although the primary determinant of FAS and its effects is the amount of maternal ethanol consumption, there is some evidence that paternal ethanol exposure may play a contributing role.¹

Ethanol use during pregnancy may lead to an increased incidence of spontaneous abortion, premature deliveries, stillbirths,¹⁹⁸ neonatal ethanol withdrawal,^28,227 and possibly carcinogenesis.¹⁵⁶ Infants may be irritable or hypertonic and may have problems with habituation and arousal. Long-term behavioral and intellectual effects include decreased IQ, learning disabilities, memory deficits, speech and language disorders, hyperactivity, and dysfunctional behavior in school.^206,295,301

Brain autopsies of children with FAS demonstrate malformations of gray and white matter, a failure of certain regions such as the corpus callosum to develop, a failure of certain cells such as the cerebellar astrocytes to migrate, and a tendency for tissue in certain regions to die.⁹⁷ The mechanisms of ethanol-induced teratogenesis are not fully elucidated.^29,121 Much of the work in animals has focused on the developing nervous system, where ethanol adversely affects nerve cell growth, differentiation, and migration, particularly in areas of the neocortex, hippocampus, sensory nucleus, and cerebellum.^117,303

Several mechanisms are potential contributors to the effects of ­ethanol.¹¹⁴ Ethanol interferes with a number of different growth factors, which may affect neuronal migration and development.³³¹ In addition, ethanol interferes with the development and function of both serotonin and N-methyl-d-aspartate (NMDA) receptors. Ethanol, or its metabolite acetaldehyde, may also cause cell necrosis directly or through the generation of free radicals and excessive apoptosis.^64,97,125 In particular, craniofacial abnormalities may be related to apoptosis of neural crest cells through the formation of free radicals, a deficiency of retinoic acid, or the altered expression of homeobox genes that regulate growth and development.³⁰³

One integrative model of ethanol-induced teratogenesis proposes that sociobehavioral risk factors, such as drinking behavior, smoking behavior, low socioeconomic status, and cultural or ethnic influences, create provocative biologic conditions, such as high peak blood ethanol concentrations, circulating tobacco constituents, and undernutrition. These provocative factors exacerbate fetal vulnerability to potential teratogenic mechanisms, such as ethanol-related hypoxia or free radical-induced cell damage.⁵

Opioids

Opioid use in pregnancy remains a significant cause of both maternal and neonatal morbidity. In past month surveys, approximately 0.2% of pregnant women report heroin use, 0.9% report the illicit use of prescription pain relievers, and 0.1% report the use of oxycodone (OxyContin).²⁶⁹ Up to 75,000 babies per year may be exposed to methadone or heroin in utero.²²² Most clinical research regarding opioid toxicity during pregnancy relates to the use of heroin or methadone.

Pregnant opioid users are at increased risk for many medical complications of pregnancy, such as hepatitis, sepsis, endocarditis, sexually transmitted infections, and AIDS, and may be at increased risk for obstetric complications, such as miscarriage, premature delivery, or stillbirth.^100,113 Some of the obstetric complications may be related to associated risk factors in addition to the opioid use. Maternal opioid use most commonly affects fetal growth.^100,113,337 There is an increased incidence of low birth weight in babies born to opioid-using mothers compared with control participants, and the effect is greater for heroin than for methadone.

There is extensive clinical experience with methadone maintenance during pregnancy. Compared with untreated heroin use, methadone maintenance during pregnancy is associated with better obstetric care, decreased risk of maternal withdrawal, increased fetal growth, decreased fetal mortality, decreased risk of HIV infection, and increased likelihood that a child will be discharged home with his or her parents.¹⁴⁶ Women who receive low-dose methadone and good prenatal care are at increased risk for pregnancy-related complications but have birth outcomes similar to nonusers.¹⁰⁰ For these reasons, methadone maintenance has become the standard opioid replacement therapy during pregnancy.¹³⁵

Nonetheless, alternatives to methadone are being explored. Just as alternative opioid replacement strategies with buprenorphine have been introduced for opioid users in general, new strategies using buprenorphine in pregnancy are being tested. In one large trial, obstetric outcomes were similar after buprenorphine treatment compared with methadone, although more women in the buprenorphine arm dropped out of the study because they did not feel well during the induction of therapy.^146,147 One group in Australia is using implantable naltrexone in pregnant patients after opioid detoxification.^137,138

The most significant acute neonatal complication of opioid use during pregnancy is the neonatal withdrawal syndrome (NWS), which is characterized by hyperirritability; GI dysfunction; respiratory distress; and vague autonomic symptoms, including yawning, sneezing, mottling, and fever.¹³⁵ Myoclonic jerks or seizures may also signify neurologic irritability. Withdrawing infants are recognizable by their extreme jitteriness despite efforts at consolation; ecchymoses and contusions may be found on the tips of their fingers or toes as a result of trauma from striking the sides of the bassinet. Approximately 50% to 90% of methadone, heroin, buprenorphine, and probably other chronic opioid-exposed newborns show some signs of withdrawal.^100,146

Opioid withdrawal symptoms typically occur within one week of birth. Heroin withdrawal usually occurs within the first 24 hours, but methadone and buprenorphine withdrawal usually occur within 2 to 3 days of age. The onset of methadone withdrawal is delayed because methadone has a larger volume of distribution and slower metabolism in the neonate and therefore an increased half-life. The onset and severity of methadone withdrawal may be related to absolute neonatal serum concentration or the rate of decline in concentration.^83,168 In one study, methadone withdrawal occurred when the plasma concentration fell below 0.06 mg/mL.²⁶²

The onset and severity of symptoms may also be related to which opioid(s) as well as other licit and illicit substances were used; how much was used chronically; how much was used near the time of delivery; the character of the labor; whether analgesics or anesthetics were used; and the maturity, nutrition, and medical condition of the neonate.⁸⁰ Acute neonatal withdrawal symptoms generally last from days to weeks, but as many as 80% of infants have been reported to have recurrence of some symptoms such as restlessness, agitation, tremors, wakefulness, hyperphagia, colic, or vomiting for 3 to 6 months.⁵⁸ In general, the incidence and severity of withdrawal are thought to be greater from methadone than from either heroin or buprenorphine.¹³⁵ When methadone was compared with buprenorphine, buprenorphine-exposed infants required lower total doses of morphine to control symptoms, had shorter courses of treatment, and had shorter hospitalizations overall.^146,147

From 5% to 7% of babies showing signs of withdrawal experience seizures, generally by 10 days after birth.¹²⁷ Seizures may be more likely after methadone withdrawal than after heroin withdrawal. These seizures do not necessarily predispose to idiopathic epilepsy; in one small study, children who had withdrawal seizures were without seizures and had normal neurologic examination findings and psychometric testing at one-year follow-up.⁸⁴

Treatment of withdrawal begins by providing a comforting environment: swaddling or tightly wrapping the infant, minimal handling or stimulation, and demand feeding. More severe symptoms may require pharmacologic therapy. The severity of withdrawal as measured by a standardized scoring scale determines the need for therapy; several scales are in use.^100,185 In general, babies who are extremely irritable; have feeding difficulties, diarrhea, or significant tremors; or cry continuously are candidates for pharmacologic therapy.¹³⁵

Opioid agonists such as morphine, methadone, tincture of opium, and paregoric; sedative–hypnotic agents such as diazepam and phenobarbital; and clonidine have all been used both individually and in various combinations to treat withdrawal symptoms. Few well-controlled trials have evaluated the relative efficacy of the different interventions or examining long-term effects of therapy.^234,235 Oral morphine is preferred to treat withdrawal symptoms because it is a short-acting pure opioid agonist, and the formulation has no additives.²⁴⁴ Clonidine and phenobarbital are beneficial as adjunctive therapies.

Opioid agonists may be more effective at preventing withdrawal seizures from heroin or methadone than from phenobarbital or diazepam.^127,151 However, sedative–hypnotic agents are commonly used by heroin users or adults maintained on methadone, and sedative–hypnotic withdrawal seizures may contribute to the overall neonatal abstinence symptomatology. In this setting, there may be a role for phenobarbital.

Infants of opioid-using mothers have a two to three times increased risk for SIDS compared with control participants.^152,153 The mechanism may be related to a decreased medullary responsiveness to CO₂, or the effect may be related to some condition of the postnatal environment.¹⁰⁰

Although young children born to opioid users do not seem to have significant differences in behavior compared to control participants, older children have increased learning problems and school dysfunction particularly related to behavior difficulties.³³⁷

Cocaine

Approximately 1% of pregnant women in the United States use cocaine at some time during their pregnancy.²²² The rate may be as high as 15% in certain populations,⁷⁷ and it is estimated that more than 100,000 infants born in the United States each year may be exposed to cocaine in utero.⁵⁶ The consequences of cocaine use during pregnancy have been extensively reviewed.^131,241,283

The incidence of abruptio placentae may be significant when related to acute cocaine use.²⁸⁷ Some uncommon perinatal problems include seizures, cerebral infarctions, and intraventricular hemorrhage.^61,241

Cocaine use is significantly related to decreases in gestational age, birth weight, length, and head circumference, although these growth parameters generally correct by several years of age.²⁸³ In addition, these growth effects are exacerbated by concomitant alcohol, tobacco, and opioid use.²⁸³ Good prenatal care can mitigate many of these adverse effects of cocaine.^193,252,337

Significant congenital malformations were reported among some infants who were exposed to cocaine in utero, specifically genitourinary malformations, cardiovascular malformations, and limb-reduction defects.^49,104 However, in one large population-based study, there was no increase in the incidence of malformations.²⁰³

Teratogenic effects are observed in animal models of in utero cocaine exposure. Decreased maternal and fetal weight gain and an increased frequency of fetal resorption were demonstrated in rats⁹⁶; sporadic physical anomalies are also observed.⁶³ Teratogenic effects similar to those observed in humans were reported in mice, including bony defects of the skull, cryptorchidism, hydronephrosis, ileal atresia, cardiac defects, limb deformities, and eye abnormalities.^{101,194,195,213} Cocaine caused hemorrhage and edema of the extremities, and, subsequently, limb-reduction defects in rats when administered during midgestation in the postorganogenic period.³²⁴

The perinatal effects of cocaine are probably mediated through a vascular mechanism. Cocaine administration in the pregnant ovine model causes increased uterine vascular resistance, decreased uterine blood flow, increased fetal heart rate and arterial blood pressure, and decreased fetal PO₂ and O₂ content.^22,333 Similar effects are reported in rats.²³⁷ Fetal hypoxia may cause rupture of fetal blood vessels and infarction in developing organ systems such as the genitourinary system^60,213,293 or the CNS.^57,82,325 Hyperthermia or direct effects of cocaine in the fetus may exacerbate these effects.⁴⁰ Limb-reduction defects similar to those attributed to cocaine can be produced after mechanical clamping of the uterine vessels.^40,326 A developing concept is that after vasospasm and ischemia, reperfusion occurs with the generation of oxygen free radicals and subsequent injury.^333,334

Despite the reported malformations and a possible mechanism, neither the human epidemiology nor the effects observed in animal models suggest a specific teratogenic syndrome. The risk of a significant malformation from prenatal cocaine exposure is low, but the effect, if one occurs, may be severe.^41,89,104

One of the greatest concerns about prenatal cocaine exposure is the potential adverse effect on the developing child, and this is an intensive area of epidemiologic research. The most common findings in early infancy are lability of behavior and autonomic regulation; decreased alertness and orientation; and abnormal reflexes, tone, and motor maturity; however, many studies show no effect, especially after controlling for confounding variables.^95,283 For some children, effects may manifest in later infancy as difficulty with information processing and learning. For school-age children, observed cognitive deficits may also be related to the home environment even for children who showed some of the typical neonatal behaviors.^102,283 Nonetheless, there is evidence of impairment in modulating attention and impulsivity, which makes handling unfamiliar, complex, and stressful tasks more difficult,^209,283 and these effects are also observed in animal models of prenatal cocaine exposure.^{89,123,182,296}

The mechanism of neurotoxicity has not been specifically elucidated. As described earlier, for many of the maternal and fetal physical defects, cocaine may have direct toxicity or, alternatively, effects may be mediated through hypoxia or oxygen free radicals. Because cocaine interferes with neurotransmitter reuptake, it is likely that cocaine also disrupts normal neural ontogeny by interfering with the trophic functions of neurotransmitters on the developing brain, in particular dysfunction of signal transduction via the dopamine D₁ receptor.^{123,182,199,208} These mechanisms may be more important in the etiology of neurobehavioral effects.

In the United States, breastfeeding is the recommended method of infant nutrition because it offers nutritional, immunologic, and psychological benefits without additional costs. Many women use prescription and nonprescription xenobiotics while breastfeeding and are concerned about the possible ill effects on their infants of these xenobiotics in the breast milk. This concern extends to the possible exposure of infants to occupational and environmental xenobiotics via breast milk.^259,278 The response to many of these concerns can be determined by the answer to the following question: Does the risk to an infant from a xenobiotic exposure via breast milk exceed the benefit of being breastfed?¹⁷⁶

Pharmacokinetic factors determine the amount of xenobiotic available for transfer from maternal plasma into breast milk; only free xenobiotic can traverse the mammary alveolar membrane. Most xenobiotics are transported by passive diffusion. A few xenobiotics, such as ethanol and lithium, are transported through aqueous-filled pores. The factors that determine how well a xenobiotic diffuses across the membrane are similar to those for other biologic membranes such as the placenta: MW, lipid solubility, and degree of ionization.

Large-molecular-weight xenobiotics, such as heparin and insulin, do not pass into breast milk. Lipid solubility is important not only for diffusion but also for xenobiotic accumulation in breast milk because breast milk is rich in fat, especially breast milk that is produced in the postcolostral period (∼3–4 days postpartum). With a pH near 7.0, breast milk is slightly more acidic than plasma. Consequently, xenobiotics that are weak acids in plasma exist largely as ionized molecules and cannot be easily transported into milk. Conversely, xenobiotics that are weak bases exist in plasma largely as nonionized molecules and are available for transport into breast milk. In breast milk, ionization of the weak base xenobiotics occurs, and the xenobiotics are concentrated as a result of ion trapping. In other words, xenobiotics that are weak bases may concentrate in breast milk. Whereas sulfacetamide (pK_a of 5.4, a weak acid) has a concentration in plasma 10 times its concentration in breast milk, sulfanilamide (pK_a of 10.4, a weak base) is found in equal concentrations in both plasma and breast milk.¹⁷⁶

The net effect of these physiologic processes is expressed in the milk-to-plasma (M/P) ratio. Xenobiotics with higher M/P ratios have relatively greater concentrations in breast milk. The M/P ratio does not, however, reflect the absolute concentration of a xenobiotic in the breast milk, and a xenobiotic with a high M/P ratio is not necessarily found at a high concentration in the breast milk. For example, morphine has an M/P ratio of 2.46 (is concentrated in breast milk), but only 0.4% of a maternal dose is excreted into the breast milk.²¹ In general, for most pharmaceuticals, approximately 1% to 2% of the maternally administered dose is presented to the infant in breast milk.¹⁷⁶

The M/P ratio has several limitations. It does not account for differences in xenobiotic concentration that may result from (1) repeat or chronic dosing, (2) breastfeeding at different times relative to maternal xenobiotic dosing, (3) differences in milk production during the day or even during a particular breastfeeding session, (4) the time postpartum (days, weeks, or months) when the measurement is made, and (5) maternal disease.

While being cognizant of the limitations, a spot breast milk xenobiotic concentration or a concentration estimate based on the M/P ratio allows a simplistic estimation of the quantity of xenobiotic to which an infant is exposed, assuming a constant breast milk concentration:

The effect of this dose on the infant depends on the bioavailability of the xenobiotic in breast milk, the pharmacokinetic parameters that determine xenobiotic concentrations in the infant, and the infant’s receptor sensitivity to the xenobiotic. These parameters are often different in neonates than in adults and may lead to xenobiotic accumulation; generally, absorption is greater, but metabolism and clearance are reduced.²⁰ These effects are exaggerated in premature infants.^247,256 The amount of most xenobiotics delivered to infants in breast milk is usually adequately metabolized and eliminated.¹⁷⁶

Many of the above considerations are theoretical, and the number of specifically contraindicated xenobiotics is quite small.¹⁴ Published guidelines on the advisability of breastfeeding during periods of maternal therapy are generally based on the expected effects of full doses in the infant or on case reports of adverse occurrences. Interestingly, when the reports of adverse effects were reviewed, 37% of cases were in infants younger than 2 weeks old, 63% were in infants younger than 1 month old, and 78% were in infants younger than 2 months old; 18% were in infants 2 to 6 months old; and only 4% were in infants older than 6 months.¹⁶ It seems, therefore, that adverse effects are most likely to be observed in the first few weeks of life, when an infant’s metabolic capacity is significantly less than that of an older infant, child, or adult.^9,79

For most xenobiotics, a risk-to-benefit analysis must be made. For example, lithium is transferred in breast milk and may lead to measurable, although subtherapeutic, serum concentrations in a breastfed infant. Although the effects of such exposure to lithium are unknown, many practitioners believe that the benefit of treating a mother’s bipolar illness outweighs the potential risk to the infant.^176,277 There may also be a small increased risk of carcinogenicity associated with exposure to some environmental xenobiotics through breast milk.²⁵⁹

Similarly, the breastfed infant of a woman who smokes is exposed to nicotine and other tobacco constituents, both by inhalation and via breast milk. Although this child may be at increased risk for respiratory illness as a result of exposure to tobacco smoke, some of the risk may be reduced by breastfeeding.^14,254

In most cases, women do not need to stop breastfeeding while using pharmaceuticals, such as most common antibiotics. However, “compatibility” with breastfeeding is generally based on a lack of reported adverse effects, which may reflect limited clinical experience with a particular xenobiotic in breastfeeding patients. Therefore, in the setting of limited information, exposure to a xenobiotic through breast milk should be regarded as a small potential risk, and the infant should receive appropriate medical follow-up. Not all “compatible” medications are safe in all situations. For instance, phenobarbital can produce CNS depression in an infant if the mother’s serum concentration is in the high therapeutic or supratherapeutic range, which often occurs while dosage adjustments are being made. Such a concentration may or may not produce CNS depression in the mother. Nalidixic acid, nitrofurantoin, sulfapyridine, and sulfisoxazole, although generally safe, can cause hemolysis in a breastfed infant with glucose-6-phosphate dehydrogenase deficiency.

When women use substances postpartum, there is delivery of some xenobiotic to the infant via breast milk, and there are rare cases reports of infants experiencing adverse effects.⁵⁹ Because of these possible direct effects on the baby, as well as the detrimental effects on the physical and emotional health of the mother and on the caregiving environment, the use of substances such as cocaine, methamphetamine, and heroin during the breastfeeding period is discouraged, and women actively using substances are discouraged from breastfeeding.¹⁴ However, women who are or have been abstinent from substance use and are participating in a treatment program are generally encouraged to breastfeed their infants.^6,176

Although ethanol is not specifically contraindicated for breastfeeding mothers, decreased milk production and adverse effects in infants are noted with maternal consumption of large amounts of ethanol.

Questions sometimes arise regarding possible lead exposure during breastfeeding. Lead crosses into breast milk from blood and is the most likely source of lead exposure for most breastfeeding infants.¹⁸⁹ Approximately 1% of US women between the ages of 15 and 49 years have blood lead concentrations greater than 5 μg/dL.⁹⁴ Some estimates suggest that breast milk concentrations are less than 3% of the maternal blood lead; therefore, if the maternal lead concentration is 5 μg/dL, then the amount of lead delivered to the infant could be 1.5 μg/L of breast milk.^118,164 This represents a relatively small exposure. In a sample of breastfed babies from one US city, the mean infant lead concentration was less than 3 μg/dL, the highest concentration was 8 μg/dL, and only 7.8% of values were greater than 5 μg/dL.¹⁸⁹ The current consensus is that the benefits of breastfeeding outweigh the relatively small exposure to lead in breast milk.³²⁹ Blood lead screening for most women is not recommended.

There are, however, some subpopulations of pregnant women at increased risk of elevated environmental lead exposure for whom blood lead screening is recommended. Risk factors for significant lead exposure in pregnant women include recent immigration, pica practices, occupational exposure, poor nutritional status, culturally specific practices such as the use of traditional remedies or imported cosmetics, and the use of traditional lead-glazed pottery for cooking and storing as well as those involved with renovation or remodeling in older homes.⁹⁴

All women should have an assessment of risk for environmental lead exposure. Women at increased risk should have blood lead screening. When possible, pregnant and postpartum women with blood lead concentrations of 5 μg/dL or higher should be removed from occupational or environmental lead sources and discouraged from practices or activities that result in increased exposure.⁹⁴ In addition, some evidence suggests that dietary supplementation of calcium can reduce the mobilization of lead in postpartum women.¹²⁶ In cases of elevated maternal lead concentrations, decisions regarding breastfeeding should be made on an individual basis.

In 2007, after the death of a breastfeeding 13 day-old infant whose mother was using codeine, the US FDA issued a public health advisory regarding the use of codeine by breastfeeding women.³¹⁵ In the initial case, the mother was found to be compound heterozygous for a CYP2D6∗2A allele and a CYP2D6∗2x2 gene duplication and therefore an “ultrametabolizer” of codeine.¹⁵⁹ In other words, codeine was metabolized to morphine at an exaggerated rate, and the infant ingested a high dose of morphine via the breast milk. The ultrametabolizer phenotype is present in up to 10% of whites and up to 30% of Ethiopians, North Africans, and Saudi Arabians.³¹⁵ In addition, both the mother and the infant were homozygous for the UGT2B7∗2 allele, which leads to elevated concentrations of morphine-6-glucuronide, an active metabolite.

Another decreased-function gene variant of ABCB1 may also have a role in this codeine toxicity. ABCB1 codes for a P-glycoprotein involved in transporting morphine out of the CNS. Decreased gene function would lead to increased accumulation of morphine in the CNS and potentially increased toxicity.²⁹⁰

Decisions on breastfeeding should be made with the informed involvement of the woman; her physicians; and when necessary, a consultant with special expertise in this field. Guidelines are available from several sources.^45,176

Physiologic differences between adults and newborn infants affect xenobiotic absorption, distribution, and metabolism.^20,154,321 Appropriate administration of xenobiotics to newborn infants therefore requires an understanding of the appropriate developmental state for medication dosing and pharmacokinetics. Even so, approximately 8% of all medication doses administered in neonatal intensive care units (NICUs) may be up to 10 times greater or lesser than the dose ordered,⁶⁷ and as many as 30% of newborns in NICUs may sustain adverse drug effects, some of which may be life threatening or fatal.²¹ Pharmacokinetic differences between adults and newborns may account for some cases of unanticipated xenobiotic toxicity that occur in newborn infants.

Gastrointestinal absorption of xenobiotics in neonates is generally slower than in adults.^20,154,321 This delay may be related to decreased gastric acid secretion, decreased gastric emptying and transit time, and decreased pancreatic enzyme activity. The GI environment of newborns and young infants may allow the growth of Clostridium botulinum and the subsequent development of infantile botulism (Chap. 41). Infantile botulism has been reported in infants several weeks of age.^139,308

Although it is uncommon, cutaneous absorption of xenobiotics may be a route of toxic exposure in a newborn.^92,268 Aniline dyes used for marking diapers are absorbed, causing methemoglobinemia,²⁶⁸ and contaminated diapers were responsible for one epidemic of mercury poisoning.²⁵ The absorption of hexachlorophene antiseptic wash has led to neurotoxicity with marked vacuolization of myelin seen microscopically.^172,204,288 The dermal application of antiseptic ethanol has caused hemorrhagic necrosis of the skin of some premature infants. Iodine antiseptics have led to hypothyroidism in mature newborns.⁵³ An increased potential for absorption and toxicity has followed the application of corticosteroids^109,266 and boric acid⁹⁰ to the skin of children with cutaneous disorders.

Other routes of exposure have led to clinical poisoning. Several children aspirated talcum powder and died.^46,220 Inhalation of mercury from incubator thermometers may be a potential risk.¹³ One child died after the ophthalmic instillation of cyclopentolate hydrochloride.²⁷

Because of differences in total body water and fat compared with adults, the distribution of absorbed xenobiotics may differ in neonates.^20,154,321 Water represents 80% of body weight in a full-term baby compared with 60% in an adult. Approximately 20% of a term baby’s body weight is fat compared with only 3% in a premature baby. The increased volume of water means that the volume of distribution for some water-soluble xenobiotics, such as theophylline and phenobarbital, is increased.

Protein binding of xenobiotics is reduced in newborns compared with adults: the serum concentration of proteins is lower, there are fewer receptor sites that become saturated at lower xenobiotic concentrations, and binding sites have decreased binding affinity.^20,154,321 Protein binding has potential relevance with respect to bilirubin, an endogenous metabolite that at very high concentrations can cause kernicterus; bilirubin competes with exogenously administered xenobiotics for protein binding sites. In vitro, certain xenobiotics, such as sulfonamides and ceftriaxone, displace bilirubin from protein receptor sites, which might increase the risk of kernicterus, although this has not been clinically demonstrated. Conversely, bilirubin may itself displace other xenobiotics, such as phenobarbital or phenytoin, leading to increased plasma xenobiotic concentrations.

Newborn infants have decreased hepatic metabolic capacity compared with adults, which may lead to xenobiotic toxicity.^20,154 For example, caffeine, used in the treatment of neonatal apnea, has an extremely prolonged half-life in newborns because CYP1A2 has only 5% of the normal adult activity.²⁰ Except for CYP1A2, most of the CYP isoenzymes reach approximately 25% of adult activity in newborns by about 1 month of age.

Two syndromes related to immature metabolic function are described. The “gasping baby syndrome,” characterized by gasping respirations, metabolic acidosis, hypotension, CNS depression, convulsions, kidney failure, and occasionally death, is attributed to high concentrations of benzyl alcohol and benzoic acid in the plasma of affected infants.^12,48,110 Benzyl alcohol, a bacteriostatic, was added to IV flush solutions and accumulated in newborns after repetitive doses. The high concentrations of benzoic acid could not be further metabolized to hippuric acid by the immature liver. Immature glucuronidation in neonates is responsible for the “gray-baby syndrome” after high doses of chloramphenicol (Chaps. 32, 55, and 57).¹³⁰

The umbilical vessels are a common site of vascular access in sick neonates. Because blood drains into the portal vein, it is possible that IV medications experience a “first-pass” effect, although whether this route of xenobiotic administration affects metabolism or clearance has not been well studied. Most functions of the kidney, including glomerular filtration rate (GFR) and tubular secretion, are relatively immature at birth²⁰; the GFR of a newborn is approximately 30% of that of an adult. Xenobiotics such as aminoglycosides and digoxin are excreted unchanged by the kidney and therefore depend on glomerular filtration for clearance. Dosing of these xenobiotics in a newborn must account for these differences.

An interesting association has been made periodically over the years between the use of erythromycin, particularly in the first 2 weeks of life, and idiopathic hypertrophic pyloric stenosis.^{66,132,196,271,297} Although erythromycin is known to interact with motilin receptors in the antrum of the stomach, no specific etiology has been defined.¹²⁴

Very little information is available to guide clinicians in the management of xenobiotic poisoning in newborn infants. Cutaneous absorption is probably already complete by the time toxicity is noted, although further exposure may be prevented. GI decontamination is not generally performed in neonates, and neonates may be at increased risk of fluid, electrolyte, and thermoregulatory problems after gastric lavage or the use of cathartic agents. Multiple-dose activated charcoal was used in a 1.4-kg, 2 week-old premature infant to treat iatrogenic theophylline toxicity.²⁸⁴ Hemodialysis, hemoperfusion, and exchange transfusion can be used in neonates to treat xenobiotic toxicity (Chaps. 10 and 32).

• Human embryos and fetuses are exposed to xenobiotics through the placenta of the pregnant woman; the neonates are exposed to xenobiotics via breast milk.

• Xenobiotic effects on developing humans include both congenital malformations as well as neurobehavioral abnormalities, which may manifest later in a child’s or adult’s life.

• The use of xenobiotics in a pregnant or breastfeeding woman is a complex area of medical practice and presents clinicians with potentially difficult management decisions regarding the benefit of therapy to the mother and the risk to the mother or fetus of xenobiotic exposure. In general, the goal is to optimize benefit to the mother while minimizing the risk to the fetus. In almost all cases, the primary approach is to fully and appropriately treat the mother.

• Appropriate management of many of the potential problems is ­facilitated by the coordinated efforts of obstetricians, perinatologists, neonatologists, pediatricians, and toxicologists.

References